The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
HOME > REGULATORY
REGULATORY
- Japan Approves Incyte’s Pemazyre, Bayer’s Vitrakvi, Novartis’ Kesimpta, and More
March 24, 2021
- Incidence of Post-Vaccine Anaphylaxis in Japan Comparable with US: MHLW
March 23, 2021
- Appraisal Results for Kymriah, Trelegy Up for Chuikyo Review on March 24; Price Cuts Likely
March 23, 2021
- COVID-19 Vaccines to Be Shipped with 6-Dose Syringes from Week of April 12, for Use in 2nd-in-Line HCPs
March 23, 2021
- Govt Disclosing Suspected Vaccine Reactions Less Frequently after Expert Advice: Minister
March 22, 2021
- MHLW Panel Hails Use of Clinical Research Data for Regulatory Submissions, but Wants Requirements to Ensure Safety
March 22, 2021
- MHLW to Set Up Medical Supply Office in April after COVID-19, Antibiotic Shortage
March 19, 2021
- Japan to Boost Screening of Coronavirus Variants: Minister
March 19, 2021
- Japan IP High Court Snubs Ex-Grad Student's Appeal over Opdivo Patent Claim
March 19, 2021
- Monitoring Panel to Require MHLW's Periodic Reports on Products Designated for Sakigake Review, Conditional Early Approval
March 18, 2021
- MHLW to Continue Looking into Cause of Generic Scandals: Minister
March 17, 2021
- All Municipalities to Get 2nd Doses for HCPs by Week of May 10: Minister
March 15, 2021
- No Significant Concerns Observed with Pfizer COVID-19 Vaccine: Japan Safety Panels
March 15, 2021
- Site Pain Common with COVID-19 Vaccine, but It Improves in 3 Days: Safety Follow-Up
March 15, 2021
- MHLW Don’t Rule Out 7 Doses per Vial, but Won’t Recommend It for Pfizer Vaccine: Minister
March 15, 2021
- MHLW Panel Determines Medical Need for 4 Drugs Including Acetaminophen
March 15, 2021
- Japan Confirming Safety of AstraZeneca’s COVID-19 Vaccine: Kato
March 15, 2021
- Olumiant, 7 More APIs Earn Orphan Designation: MHLW
March 12, 2021
- 2nd-Dose Shot Starts for COVID-19 Vaccination in Japan
March 12, 2021
- AMED to Fund 22 More Projects to Develop COVID-19 Treatments
March 11, 2021
ページ
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
After decades in recruitment, I say from experience that there’s a particular way to attract candidates to a given role. Do it right, and you’ll have talent chasing you. Get it wrong, and you’ll be left listening to the crickets…